Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 9:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 356 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Newly Diagnosed Glioblastoma Clear all
Not listed Phase 2 Interventional

Hyperbaric Hyperoxygenation With Radiotherapy and Temozolomide in Adults With Newly Diagnosed Glioblastoma

NCT00936052
View directory record Official record
Conditions
Glioblastomas, Gliosarcoma
Interventions
Hyperbaric Oxygen Therapy
Other
Lead sponsor
Neurological Surgery, P.C.
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Commack, New York • Great Neck, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2010 · Synced Oct 13, 2026, 9:14 PM EDT
Recruiting Phase 2 Interventional

WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

NCT05879250
View directory record Official record
Conditions
Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma
Interventions
Biospecimen Collection, Magnetic Resonance Imaging, Radiation Therapy, STAT3 Inhibitor WP1066, Surgical Procedure
Procedure · Radiation · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Chicago, Illinois • Warrenville, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 13, 2026, 9:14 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)

NCT04752813
View directory record Official record
Conditions
Glioblastoma, Glioblastoma Multiforme
Interventions
BPM31510, Vitamin K1, Temozolomide (TMZ), Radiation
Drug · Other · Radiation
Lead sponsor
BPGbio
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
11
States / cities
Los Angeles, California • Palo Alto, California • Santa Barbara, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 13, 2026, 9:14 PM EDT
Completed Phase 2 Interventional Results available

Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer

NCT00445965
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer, Melanoma (Skin), Metastatic Cancer, Neuroblastoma, Ovarian Cancer, Retinoblastoma, Sarcoma, Small Intestine Cancer
Interventions
DNA analysis, immunologic technique, pharmacological study, iodine I 131 monoclonal antibody 3F8, 131I-3F8
Genetic · Other · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 13, 2026, 9:14 PM EDT
Completed Phase 1 Interventional

GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas

NCT03576612
View directory record Official record
Conditions
Glioma, Malignant
Interventions
AdV-tk, Valacyclovir, Radiation, Temozolomide, Nivolumab, Laboratory Biomarker Analysis
Biological · Drug · Radiation + 1 more
Lead sponsor
Candel Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
5
States / cities
Boston, Massachusetts • Detroit, Michigan • Winston-Salem, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2025 · Synced Oct 13, 2026, 9:14 PM EDT
Completed Phase 1 Interventional Results available

Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma

NCT03072134
View directory record Official record
Conditions
Glioma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma, Glioblastoma Multiforme, Astrocytoma, Grade III, Astrocytoma, Grade IV, Brain Cancer
Interventions
Neural stem cells loaded with an oncolytic adenovirus
Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Duarte, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 20, 2023 · Synced Oct 13, 2026, 9:14 PM EDT
Completed Phase 2 Interventional Results available

A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)

NCT01280552
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
ICT-107, Placebo DC
Biological
Lead sponsor
Precision Life Sciences Group
Industry
Eligibility
18 Years to 80 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
25
States / cities
South Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Oct 13, 2026, 9:14 PM EDT
Completed No phase listed Observational

Analysis of Cell Count, Viability, and Immunogenicity of Discarded Newly Diagnosed Glioblastoma Tissue or Solid Tumor Tissues

NCT04822688
View directory record Official record
Conditions
Glioblastoma, Malignant Solid Neoplasm
Interventions
Biospecimen Collection
Procedure
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 13, 2026, 9:14 PM EDT
Active, not recruiting Early Phase 1 Interventional

Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma

NCT05076513
View directory record Official record
Conditions
Glioblastoma, Glioblastoma Multiforme, Glioma, GBM, Glioma, Malignant, Glioblastoma Multiforme of Brain
Interventions
Niraparib, Radiation therapy
Drug · Radiation
Lead sponsor
Nader Sanai
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 13, 2026, 9:14 PM EDT
Completed Phase 1 Interventional

Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma

NCT00650923
View directory record Official record
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Recurrent Adult Brain Tumor
Interventions
ziv-aflibercept, radiation therapy, temozolomide, pharmacological study, laboratory biomarker analysis
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated May 30, 2014 · Synced Oct 13, 2026, 9:14 PM EDT
Completed Phase 2 Interventional Results available

Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma

NCT00782756
View directory record Official record
Conditions
Brain Cancer, Malignant Glioma
Interventions
radiotherapy (RT) in combination with temozolomide and bevacizumab
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
3
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Oct 13, 2026, 9:14 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00731731
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
Interventions
3-Dimensional Conformal Radiation Therapy, Cognitive Assessment, Laboratory Biomarker Analysis, Temozolomide, Vorinostat
Radiation · Procedure · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
110
States / cities
Scottsdale, Arizona • San Francisco, California • Jacksonville, Florida + 67 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Oct 13, 2026, 9:14 PM EDT
Terminated Phase 2 Interventional

Phase II Study of Temozolomide in Newly Diagnosed Glioblastoma

NCT00365222
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
Temozolomide
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
70 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 22, 2009 · Synced Oct 13, 2026, 9:14 PM EDT
Completed Phase 1 Interventional Results available

Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas

NCT01922076
View directory record Official record
Conditions
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Glioblastoma, Gliosarcoma
Interventions
Adavosertib, Laboratory Biomarker Analysis, Pharmacological Study, Radiation Therapy
Drug · Other · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
37 Months to 21 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Oct 13, 2026, 9:14 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma

NCT03197506
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma, Supratentorial Glioblastoma
Interventions
External Beam Radiation Therapy, Laboratory Biomarker Analysis, Pembrolizumab, Radiation Therapy, Temozolomide, Therapeutic Conventional Surgery
Radiation · Other · Biological + 2 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
3
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 13, 2026, 9:14 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors

NCT04478279
View directory record Official record
Conditions
Glioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer, Glioblastoma Multiforme, GBM, Brain Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Prostate Cancer, Melanoma Recurrent, Prostate Cancer Metastatic, Recurrent Glioblastoma, Newly Diagnosed Glioblastoma
Interventions
ST101, Temozolomide, Radiation
Drug · Radiation
Lead sponsor
Sapience Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
7
States / cities
San Francisco, California • Denver, Colorado • Warrenville, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 13, 2026, 9:14 PM EDT
Active, not recruiting Phase 3 Interventional

Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma

NCT05095376
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
Lomustine, Magnetic Resonance Imaging, Photon Beam Radiation Therapy, Questionnaire Administration, Temozolomide
Drug · Procedure · Radiation + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years to 70 Years
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
418
States / cities
Fairbanks, Alaska • Fayetteville, Arkansas • Little Rock, Arkansas + 304 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 13, 2026, 9:14 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00003996
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
carmustine, chemotherapy, cisplatin, etoposide, radiation therapy
Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
19
States / cities
Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Oct 13, 2026, 9:14 PM EDT
Completed Phase 3 Interventional Results available

An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)

NCT02617589
View directory record Official record
Conditions
Brain Cancer
Interventions
Nivolumab, Temozolomide, Radiotherapy
Drug · Radiation
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Oct 13, 2026, 9:14 PM EDT
Completed Phase 2 Interventional

Irinotecan Followed by Radiation Therapy and Temozolomide in Treating Children With Newly Diagnosed Brain Tumor

NCT00004068
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
irinotecan hydrochloride, temozolomide, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
3 Years to 21 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 4, 2011 · Synced Oct 13, 2026, 9:14 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Hydroxychloroquine, Radiation, and Temozolomide Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00486603
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
hydroxychloroquine, temozolomide, pharmacological study, Radiation
Drug · Other · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
9
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Oct 13, 2026, 9:14 PM EDT
Completed Not applicable Interventional

Nativis Voyager for Newly Diagnosed GBM

NCT03276286
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Nativis Voyager
Device
Lead sponsor
Nativis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
7
States / cities
Tucson, Arizona • Encinitas, California • Santa Monica, California + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Oct 13, 2026, 9:14 PM EDT
Completed Phase 1 Interventional

Temozolomide and O6-benzylguanine in Treating Patients With Newly Diagnosed, Recurrent, or Progressive Anaplastic Glioma

NCT00006474
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
O6-benzylguanine, temozolomide, conventional surgery
Drug · Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 13, 2026, 9:14 PM EDT
Completed Phase 2 Interventional Results available

Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme

NCT02465268
View directory record Official record
Conditions
Glioblastoma Multiforme, Glioblastoma, Malignant Glioma, Astrocytoma, Grade IV, GBM
Interventions
pp65-shLAMP DC with GM-CSF, unpulsed PBMC and saline, Td, Saline, pp65-flLAMP DC with GM-CSF
Biological · Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
3
States / cities
Gainesville, Florida • Orlando, Florida • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 13, 2026, 9:14 PM EDT